IRVINE, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- ChromaDex Corporation (OTC Bulletin Board: CDXC), a leader in phytochemical reference standards and related contract analysis and research services, today announced that it has entered into a global agreement with Kappa Bioscience AS (Oslo, Norway) to supply analytical reference standards, quality control methods and related analytical testing services for Vitamin K2, Menaquinone-7(MK-7) in raw materials and finished goods.
"With increasing market demand for Vitamin K2 MK-7, there will be an increase in demand for reference standards, quality control methods, research tools and analytical services," said Frank Jaksch, CEO and co-founder of ChromaDex. "Since MK-7 is a vitamin product manufactured from different sources, it is critical that testing procedures are in place to ensure the quality and consistency of any MK-7 related ingredient or product."
Vitamin K2 is shown to have significant importance for optimal utilization of calcium in the body related to bone and cardiovascular health. Studies indicate that the Western diet is deficient in Vitamin K2. Thus, daily supplementation is expected to be beneficial for the bone building process as well as for cardiovascular health.
"The market needs a reliable and impartial third party expert like ChromaDex to bring clarity to Vitamin K analysis," said Egil Greve, CEO of Kappa Bioscience. "To date it has been difficult, if not impossible, to verify the label claims of Vitamin K2 in nutritional products. We expect that industry interest and confidence in Vitamin K2 will grow now that we can all confirm fortification," he added.
About ChromaDexChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. The company has worldwide exclusive patent rights related to pterostilbene. For more information, visit http://www.chromadex.com/ or follow ChromaDex on Twitter @ChromaDex.
About Kappa BioscienceKappa Bioscience is the innovative leader and first mover with high purity vitamin K2 as menaquinone-7 (MK-7). Kappa Bioscience is a Norwegian based entity with substantial resources and knowledge about vitamins and vitamin K2 in particular. Kappa Bioscience is currently the only vendor with vitamin K2 as pure MK-7 in various formulations, following a traditional vitamin production process with proprietary and innovative new steps. The company is operating in the US through Xsto Solutions and has its manufacturing in NJ, USA. For further information, visit http://www.kappabio.comCHROMADEX CONTACTSInvestor InquiriesLiviakis Financial Communications, Inc.John M. Liviakis, President415-389-4670John@Liviakis.comChromaDex Contact Jenny RoblesAdministrative Assistant to the CEO10005 Muirlands Blvd, Suite G, Irvine, CA firstname.lastname@example.orgMedia ContactMegan LavineCanale Communications3033 5th Ave., Suite 400, San Diego, CA email@example.comKAPPA BIOSCIENCE CONTACTSEgil GreveChief Executive Officer+47 95 10 firstname.lastname@example.orgArne Johan GrimsboVP Strategy & Bus. Dev+47 90 email@example.com
|SOURCE ChromaDex Corporation|
Copyright©2010 PR Newswire.
All rights reserved